rediff.com

NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  

Rediff News  All News 
Rediff.com  » Business » Sensex jumps 227 points as rate-cut hopes aid

Sensex jumps 227 points as rate-cut hopes aid

Last updated on: April 25, 2013 16:36 IST

The BSE Sensex rose for a fourth straight day on Thursday, closing at their highest level in more than a month as expectations of a rate cut at the Reserve Bank of India's (RBI) upcoming annual monetary policy review continued to keep sentiment bullish.

Shares were also buoyed by positive global sentiment on hopes major central banks will ease monetary policy further or continue to keep it loose for long.

The weak inflation print in March and the recent declines in oil and gold prices have stoked hopes of at least a 25 basis point cut in benchmark interest rates at the RBI's annual policy review on May 3.

"If the current rally has to sustain, good news has to come in from the RBI policy. Monsoon forecast would also add to the current growth versus slowdown conundrum," said Deven Choksey, managing director, KR Choksey Securities.

"Political uncertainty would, however, remain a joker in the pack," he added.

The benchmark BSE index rose 1.19 per cent, or 227.49 points, to 19,406.85, its highest close since March 15. The broader NSE index rose 1.36 per cent, or 79.40 points, to 5,916.30, its highest closing level since March 11.

Asian shares rose with recovering commodities and views that a run of weak global economic data will encourage major central banks to keep or deepen their monetary stimulus improving risk sentiment, but weak data undermined the dollar.

Jet Airways Ltd <JET.NS> closed up 10.8 per cent as profit-taking crept in after the stock rose almost 20 per cent in pre-open trades on its $379 million stake sale deal with Etihad.

The deal set a valuation benchmark for further investment in Indian airlines, with budget carrier SpiceJet Ltd <SPJT.BO> frequently the subject of stake sale reports.

SpiceJet closed up 18.2 per cent, while Kingfisher Airlines Ltd <KING.NS> gained 0.7 per cent.

Dr. Reddy's Laboratories Ltd <REDY.NS> gained as much as 5.2 per cent to an all-time high of 2,000 rupees before closing up 4.8 per cent on hopes growth in the domestic market would remain strong.

Other pharmaceutical firms also gained with Lupin Ltd <LUPN.NS> closing up 1.7 per cent and Sun Pharmaceutical Industries Ltd <SUN.NS> ending higher 3.1 per cent.

Idea Cellular Ltd <IDEA.NS> gained as much as 4.2 per cent on expectations earnings for the January-March quarter due after market hours would beat estimates, but later gave up gains to close 1.4 per cent higher.

Rate-sensitive banking stocks also continued to gain on rate-cut hopes. Axis Bank Ltd <AXBK.NS> finished up 4.1 per cent after better-than-hoped March quarter results, while ICICI Bank Ltd <ICBK.NS> rose 1.4 per cent ahead of its results on Friday.

The government's hefty cash holdings, now parked at the central bank, may soon be deposited at commercial banks, sources told Reuters.

The move would add liquidity to the banking system and make monetary policy more effective by making it easier for banks to cut lending rates and was also a factor boosting banks.

Among the losers, technology shares which have been falling after disappointing results and guidance continued to see more selling, possibly on the back of roll-over of short positions on the last day of the April derivatives contract expiry.

The NSE technology index <.CNXIT> has lost nearly 16 per cent since the start of the current downtrend on April 12.

The Nifty has gained 4.1 per cent since the expiry of the last derivatives contract on March 28.

Infosys Ltd <INFY.NS> fell 1.5 per cent, while Tata Consultancy Services <TCS.NS> dropped 2 per cent and Wipro <WIPR.NS> slipped 2.1 per cent.

Additional reporting by Abhishek Vishnoi

Swati Bhat in Mumbai
Source:
© Copyright 2014 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.